期刊文献+

Elafin在肿瘤坏死因子-α诱导的炎性反应中的抗炎机制 被引量:1

The anti-inflammatory mechanism of Elafin in tumor necrosis factor(TNF)-α-induced inflammation reaction
下载PDF
导出
摘要 目的探讨Elafin的抗炎机制。方法体外培养人支气管上皮细胞系16HBE细胞,将已构建好的pEG-FP-N1-Elafin载体转染到细胞中,并以空质粒载体作其对照,以外源性肿瘤坏死因子(TNF)-α作为刺激物共同孵育。间接免疫荧光细胞化学法结合激光共聚焦显微镜检测细胞核中核因子(NF)-κB的活性,ELISA检测细胞上清液中炎性介质(选取IL-1β、IL-8作为代表)的含量,免疫共沉淀法结合Western blot检测小泛素样修饰蛋白(SU-MO)-1-p-IκBα含量。结果重组质粒组的细胞中NF-κB的活性和IL-1β、IL-8的生成量与空质粒载体组细胞相比明显降低,而SUMO-1-p-IκBα的含量则显著升高(P<0.01)。结论Elafin能够通过促进IκBα的类泛素化阻止NF-κB的活化,下调前炎性介质的生成,从而发挥其抗炎作用。 Purpose To investigate the mechanism of Elafin anti-inflammatory action.Methods After cultivating 16HBE cells in vitro,the constructed pEGFP-N1-Elafin eukaryotic expression vector was transfected into the cells,with empty plasmid as a vector control.The cells were then incubated with exogenous TNF-α.The NF-κB activity in nuclear was detected by immunofluorescence and laser scanning confocal microscope,the IL-1β and IL-8 production was assayed by ELISA and the SUMO-1-p-IκBα production was assayed by co-immunoprecipitation and Western blot.Results The NF-κB activity,the IL-1β and IL-8 production of the experimental group were significantly lower than those of the empty plasmid group.The SUMO-1-p-IκBα production of the experimental group was significantly higher than that of the empty plasmid group(all P〈0.01).Conclusion Elafin prevents NF-κB activation via an effect on IκBα sumoylation,and it then reduces proinflammatory cytokine production,thus playing a role of anti-inflammatory.
出处 《中国生化药物杂志》 CAS CSCD 北大核心 2011年第3期169-172,共4页 Chinese Journal of Biochemical Pharmaceutics
基金 国家自然科学基金(81070031) 国家自然科学基金中俄合作项目(81011120108)
关键词 ELAFIN 核因子-ΚB 小泛素样修饰蛋白-1 类泛素化 抗炎作用 Elafin nuclear factor-κb small ubiquitin-like modifier-1 sumoylation anti-inflammatory action
  • 相关文献

参考文献8

  • 1Li Q,Verma I M. NF-κB regulation in the immune system[ J]. Nat Rev Immunol,2002,2(10) :725-734.
  • 2吴雪梅,刘霞,王琛,谢红.核因子-κB特异性抑制剂小白菊内酯在大鼠心肌组织的药效时间[J].中国生化药物杂志,2009,30(6):365-367. 被引量:2
  • 3Desterro J M, Rodriguez M S, Hay R T. SUMO-1 modification of ikappaBalpha inhibits NF-kappaB activation[ J]. J Mol Cell, 1998, 2(2) :233-239.
  • 4Williams S E, Brown T I, Roghanian A, et al. SLPI and elafin:one glove, many fingers[ J]. Clin Sci(Lond) ,2006,110( 1 ) :21-55.
  • 5杨捷,周向东.天然内生抗菌多肽elafin真核表达载体的构建及在真核细胞的表达[J].中国抗生素杂志,2005,30(10):608-610. 被引量:6
  • 6Balkwill F, Mantovani A. Inflammation and cancer: back to Virc- how? [J].Lancet,2001,357(9255):539-545.
  • 7Schalkwijk J,Wiedo O, Hirose S. The trappin gene family: proteins defined by an N-terminal transglutaminase substrate domain and a C-terminal four-disulphide core [ J ]. J Bio Chem, 1999,340 ( Pt3 ) : 569-577.
  • 8Kim Y I, Song K E, Ryeon H K, et al. Enhanced inflammatory cyto- kine production at ischemia-reperfusion in human liver resection [ J ].Hepatogastroenterology ,2002,49 ( 46 ) : 1077 -1082.

二级参考文献19

  • 1张迎媚,薛东波,王海洋,张伟辉.细菌脂多糖对急性胰腺炎大鼠核因子-κB及肿瘤坏死因子的影响[J].中华医院感染学杂志,2005,15(7):747-750. 被引量:7
  • 2Funnaki H, Shimizu K, Harada S, et al. Essential role for nuclear factor kappaB in ischemic preconditioning for ischemic-reperfusion injury of the mouse liver[J]. Transplantation,2002,74(4):551-556.
  • 3Pagliaro P, Gattullo D, Rastaldo R, et al. Ischemic preconditioning from the first to the second window of protection[J]. Life Sci,2001,69( 1 ): 1-15.
  • 4Pajak B, Gajkowska B, Orzechowski A. Molecular basis of parthenolide- dependent proapoptotic activity in cancer cells[J]. Folia Histochem Cytobiol, 2008,46 (2) : 129-135.
  • 5Liu S F, Asrar B M. NF-κB activation as a pathological mechanism of septic shock and inflammation[J]. Am J Physiol Lung Cell Mol Physiol, 2006,290 (4) : L622-L645.
  • 6Han S J, Ko H M, Choi J H, et al. Molecular mechanisms for lipopolys accharide-induced biphasic activation of nuclear factor-kappa B (NF-κB) [J] .J Biol Chem,2002,277(47) :44715-44721.
  • 7Haudek S B, Spencer E, Bryant D D,et al. Overexpression of cardiac 1- κBα prevents endotoxin-induced myocardial dysfunction[J]. Am J Physiol Heart Circ Phsiol,2001,280(3) :H962-H968.
  • 8Lv R, Zhou W, Yang J J, et al. Hydroxyethyl starch inhibits intestinal production of cytokines and activation of transcription factors in endotoxaemic rats[J].J Int Med Res,2005,33(4):379-388.
  • 9Demoule A, Divangahi M, Yahiaoui L, et al. Endotoxin triggers nuclear factor-κB-dependent up-regulation of multiple proinflammatory genes in the diaphragm[ J ]. Am J Respir Crit Care Med, 2006, 174 ( 6 ) : 646- 653.
  • 10Garrean S, Gao X P, Brovkovych V, et al. Caveolin-1 regulates NF-kappaB activation and lung inflammatroy response to sepsis induced by lipopolysaccharide [ J ]. J Immunol, 2006,177 (7) : 4853-4860.

共引文献6

同被引文献9

  • 1Vogelsang GB, Lee L, Bensen-Kennedy DM, et al. Pathogenesis and treatment of graft-versus-host disease after bone marrow trans- plant. Annu Rev Med,2003,54:29-52.
  • 2Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet,2009,373 : 1550-1561.
  • 3Antin JH, Deeg HJ. Clinical spectrum and pathophysiology of acute graft-'~s-host disease in graft-vs.-host disease. New York: Marcel Dekker, 2005: 369-381.
  • 4Cutler C, Antin JH. Manifestations and treatment of acute graft- versus-host disease in Thomas' Hematopoietic Cell Transplanta- tion. Oxford: Blackwell, 2009 : 1287-1303.
  • 5Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft- versus-host disease with prednisolone: significant survival advan- tage for day + 5 responders and no advantage for nonresponders re- ceiving anti-thymocyte globulin. Blood,2006,107:4177-4181.
  • 6Deeg Hi. How I treat retYactory acute GVHD. Blood,2007,109: 4119-4126.
  • 7Paczesny S, Braun TM, Levine JE, et al. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Meal, 2010, 2: 13ra2.
  • 8Moreau T, Baranger K, Dad6 S,et al. Multifaceted roles of human elafin and secretory leukocyte proteinase inhibitor ( SLPI ), two serine protease inhibitors of the chelonianin family. Biochimie, 2008,90:284-295.
  • 9Pfundt R, Wingens M, Bergers M, et al. TNF-alpha and serum induce SKALP/elafin gene expression in human keratinocytes by a p38 MAP kinase-dependent pathway. Arch Dermatol Res, 2000,292 : 180-187.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部